CANF Stock Catalyst: Can-Fite BioPharma Announces 9-Year Survival with Complete Response in Namodenoson-Treated Patient

Nov 17, 2025 · 3:59pm ET

Patient treated for advanced liver cancer shows complete response.

Max move

+94.6%

High of day $14.40

Sparker timei

3:59pm ET

CANF · Nov 17, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Can-Fite BioPharma Ltd. announced on November 18, 2025, that a patient treated with Namodenoson has achieved an overall survival of 9 years with a complete response to treatment for advanced liver cancer. The announcement highlights the potential efficacy of Namodenoson in treating this severe condition.

The patient's survival duration and response are notable, considering the severe prognosis typically associated with advanced liver cancer. Over 1,600 patients have been treated with Namodenoson as part of the company's clinical trials.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CANF sparks.

Download Sniper App →

Catch the next CANF-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →